The adenovirus type 5 E1B-55 kDa oncoprotein forms a complex with the tumor suppressor p53 and inactivates it. E1B-55 kDa and p53 are each capable of forming oligomers. We mapped the oligomerization domain of E1B-55 kDa to the central portion of the protein. Disturbing E1B-55 kDa self-association by point mutations at residues 285/286 or 307 not only impairs its intracellular localization to the cytoplasmic clusters, but in addition, its association with p53. Strikingly, tetramerization of p53 is also required for efficient association with E1B-55 kDa. Moreover, two different E1B-55 kDa mutants defective for p53 binding but proficient for oligomerization can trans-complement each other for p53 relocalization. We propose that the homo-oligomerization of each component enables efficient interaction between E1B-55 kDa and p53 through increased avidity.
Introduction p53 is at the center of the cell-cycle sensory system. Its activation can induce different cell fates depending on input signals. It can cause cell-cycle arrest or lead to apoptosis (Horn and Vousden, 2007; Olivier et al., 2009) . It is a transcription factor and can induce cellcycle regulation of proapoptotic genes by binding to their promoters. Its N-terminal region contains a transactivation and a proline-rich domain. The central region comprises the DNA binding domain. Finally, the C-terminal portion contains a tetramerization domain and a regulatory region. p53 is only active in a tetrameric state, regarding transcriptional activity, and tumor suppression. Although p53 monomers can bind to DNA and stimulate transcription under specific circumstances (Chene, 2001) , the affinity of this binding is much weaker (Balagurumoorthy et al., 1995) .
The Mdm2 oncoprotein binds p53 and mediates its ubiquitination, marking p53 for degradation (Haupt et al., 1997; Kubbutat et al., 1997) . Although the direct Mdm2/p53 interaction has been mapped to the N-terminal portion of p53 (Lin et al., 1994) , the oligomerization domain of p53 enhances the interaction of the two proteins and p53 degradation. Only high Mdm2 concentrations allowed the degradation of monomeric p53 (Kubbutat et al., 1998) .
Viral oncogenes interact with p53, raising the possibility that these interactions also rely on the ability of either component to homo-oligomerize. The adenovirus type 5 E1B-55 kDa protein functions as an antagonist to p53. It can bind p53 and inactivate its transactivation domain (Sarnow et al., 1982a) . E1B-55 kDa mostly localizes to cluster-shaped aggregates in the cytoplasm that were reported to represent aggresomes by some groups (Liu et al., 2005) but found distinct from aggresomes by others (Zhao and Liao, 2003) , p53 is relocalized to these clusters by E1B-55 kDa (Zantema et al., 1985; Blair Zajdel and Blair, 1988) . Together with another viral protein, E4orf6, E1B-55 kDa also induces p53 ubiquitination and degradation (Querido et al., 1997 (Querido et al., , 2001a Roth et al., 1998; Steegenga et al., 1998) . Purified E1B-55 kDa has been shown to form dimers (Martin and Berk, 1998 ). Here we provide evidence indicating intracellular E1B-55 kDa oligomerization. We map a domain essential for oligomerization to the central region of the protein. E1B-55 kDa oligomerization seems essential for proper localization. Moreover, the E1B-55 kDa/p53 interaction seems to depend strongly on the ability of each component to oligomerize. Thus, avidity effects appear to enable the interaction of E1B-55 kDa with the p53 tetramer.
Results

A central portion of E1B-55 kDa is necessary for its self-association
It has been shown previously that purified E1B-55 kDa can form dimers (Martin and Berk, 1998) . To test if dimerization can be detected in cells, we co-transfected H1299 cells (p53À/À) to synthesize differentially tagged E1B-55 kDa carrying the HA or the MYC tag. Cell lysates were then subjected to immunoprecipitation with an antibody to the HA tag. Self-association of wild-type E1B-55 kDa was detected through co-precipitated MYC-E1B-55 kDa ( Figure 1a ). To identify regions important for oligomerization, we first tested large deletion mutants (data not shown) and then smaller deletions that abolished the co-precipitation with wildtype E1B-55 kDa (Figures 1a and b) . These deletions cover a specific region, amino acids 241-320, that has been previously characterized as having homology to ribonucleoprotein (RNP) domains and weak unspecific RNA binding activity (Horridge and Leppard, 1998) . From here on, we refer to this region as an oligomerization domain. E1B-55 kDa can self-associate in a cellular context, and this requires a conserved central portion of the protein.
E1B-55 kDa oligomerization segregates with proper localization Next, we analyzed how deletions in the central portion affect the intracellular localization of E1B-55 kDa. E1B-55 kDa can form characteristic cytoplasmic clusters (Zantema et al., 1985; Blair Zajdel and Blair, 1988) . Immunofluorescence analysis of transfected H1299 cells showed that none of the E1B-55 kDa oligomerization mutants could form these clusters. Rather, these mutants of E1B-55 kDa were evenly distributed within the cytoplasm (Figures 2a; Supplementary Figure S1 ). We then investigated the interaction of E1B-55 kDa with E4orf6 protein. Wild-type E1B-55 kDa was relocalized to the nucleus by E4orf6, as reported previously (Goodrum et al., 1996) . In contrast, all of the E1B-55 kDa deletion mutants remained mainly cytoplasmic despite the presence of E4orf6 (Figure 2b ).
C-terminal truncation mutant of E1B-55 kDa but not the central domain deletion mutants can be relocalized to cytoplasmic clusters by wild-type E1B-55 kDa A C-terminal portion of E1B-55 kDa has been found necessary for its localization to cytoplasmic clusters (Teodoro and Branton, 1997; Schwartz et al., 2008) . We used this as an independent means to observe intracellular self-association. A C-terminal truncation mutant with a stop codon at position 396 (E1B Stop396) was found diffusely distributed in the cytoplasm, as determined by immunofluorescence (Figure 3a) . However, co-expressing differentially tagged wild-type E1B-55 kDa led to the detection of both proteins in clusters (Figures 3a and b Figure 1 Self-association of E1B-55 kDa, and failure of deletion mutants to so. (a) Lysates from H1299 cells co-transfected with expression constructs for differentially tagged E1B-55 kDa proteins (500 ng HA-tagged E1B-55 kDa constructs and 1500 ng MYCtagged wild-type E1B-55 kDa) were subjected to immunoprecipitation (IP) with the anti-HA antibody. 2% of the input lysates and approximately 20% of the immunoprecipitates were analyzed by immunoblotting and staining with anti-HA and anti-MYC antibodies. hIgG, heavy chain of immunoglobulin G. (b) Primary structure of E1B-55 kDa with putative functional regions. Nuclear import signal (NLS),position 83-93; putative ribonucleoprotein (RNP) motif homology region, position 250-308. Scheme modified from Gonzalez and Flint (2002) . Protein sequence alignment between the Ad5 E1B-55 kDa protein and homologues from different adenovirus groups. Identical residues are marked in black, others in gray. The deleted amino acids in the E1B-55 kDa mutants used here are indicated by bars above the alignment. . At 24 h after transfection, the cells were immunostained with the monoclonal antibody 2A6 specific for E1B-55 kDa, followed by a green-fluorescently labeled secondary antibody. The locations of the nuclei were visualized by 4 0 -6-diamidino-2-phenylindole (DAPI) staining. The sites of cytoplasmic clusters containing wild-type E1B-55 kDa are marked by arrowheads. Bar ¼ 20 mm. (b) Relocalization of E1B-55 kDa by E4orf6. Expression plasmids for HA-tagged E1B-55-kDa (150 ng) and E4orf6 (450 ng) or 'empty' vector constructs were co-transfected into H1299 cells as indicated, followed by staining with a rabbit anti-HA antibody to detect E1B-55 kDa and the mouse monoclonal anti-E4orf6 antibody (RSA3). Corresponding secondary antibodies conjugated to green and red fluorescent dyes were used. The locations of the nuclei were visualized by DAPI staining. Bar ¼ 20 mm.
Self-association of E1B-55 kDa M Morawska-Onyszczuk et al oligomerization domain remained cytoplasmic even after co-expression with wild-type E1B-55 kDa ( Figures  3a and b) . We conclude that the central and the Cterminal regions of E1B-55 kDa are necessary for the formation of cytoplasmic clusters, but only the central domain seems essential for association with wild-type E1B-55 kDa. Student's t-test was performed to calculate the significance levels by which the indicated values are distinct. *Po0.02; **Po0.001 (cf. Supplementary Table S1 ).
Self-association of E1B-55 kDa M Morawska-Onyszczuk et al efficiently relocalize p53 from the nucleus to the cytoplasm (Figure 4a ), as observed previously (Zantema et al., 1985; Blair Zajdel and Blair, 1988) . In contrast, on co-expression with E1B-55 kDa deletion mutants, p53 remained nuclear ( Figure 4a ). Next, we assessed the inhibition of p53 activity by mutants of E1B-55 kDa in a luciferase reporter assay. H1299 cells were co-transfected to express p53 and E1B-55 kDa, together with a firefly luciferase plasmid containing a p53-inducible promoter and a plasmid that constitutively expressed renilla luciferase for normalization. As expected, wildtype E1B-55 kDa could efficiently block p53-mediated transactivation ( Figure 4b ). However, E1B-55 kDa oligomerization mutants almost completely lost this ability ( Figure 3b ). E1B-55 kDa not only inhibits p53 but, together with E4orf6, induces p53 ubiquitination and subsequent degradation (Querido et al., 1997; Steegenga et al., 1998) . The levels of p53 were assessed Interaction of p53 with E1B-55 kDa oligomerization mutants. (a) Impact of E1B-55 kDa mutants on p53 localization. H1299 cells were co-transfected expression constructs for HA-tagged E1B-55 kDa (300 ng) and wild-type p53 (30 ng), followed by immunostaining with a mouse monoclonal antibody to the HA-tagged and a rabbit anti-p53 antibody (FL393). Nuclei were visualized by 4 0 -6-diamidino-2-phenylindole (DAPI) staining. Bar ¼ 20 mm. (b) Impact of E1B-55 kDa mutants on p53 activity. Expression plasmids for p53 (50 ng), E1B-55 kDa mutants (500 ng) or b-galactosidase (500 ng) were co-transfected along with 100 ng of a p53 responsive firefly luciferase reporter plasmid, pBP100luc (Roth et al., 1998) , and 50 ng of a Tk promoter-driven renilla luciferase reporter plasmid into H1299 cells as indicated. At 24 h after transfection, both luciferase activities were determined. Firefly luciferase activities were divided by renilla luciferase activities and then normalized to the wild-type p53 activity alone. The experiments were performed in triplicates, mean and standard deviations are indicated. *Po0.01. (c) Ability of E1B-55 kDa mutants to mediate p53 degradation. H1299 cells were transfected with plasmids to express p53 (50 ng), E1B-55 kDa (100 ng) and E4orf6 (450 ng) or 'empty' vectors as indicated. After 24 h the cells were harvested, followed by immunoblot analysis with the indicated antibodies. Enhanced green fluorescent protein (EGFP) and b-actin served as transfection and loading controls, respectively.
Self-association of E1B-55 kDa M Morawska-Onyszczuk et al by immunoblot analysis. As expected, p53 levels dropped on co-expression with wild-type E1B-55 kDa and E4orf6. However, the oligomerization mutants of E1B-55 kDa did not induce p53 degradation (Figure 4c ), in accordance with the lost colocalization with E4orf6 and p53. Hence, the central domain of E1B-55 kDa is needed for efficient p53 degradation.
E1B-55 kDa mutants F307A and FY285AA largely fail to self-associate To identify specific amino-acid residues responsible for E1B-55 kDa oligomerization, we created a series of single substitution mutants. Three phenylalanine residues within the conserved region 245-310 of E1B-55 kDa were mutated to alanines and analyzed regarding localization and p53 antagonism. Mutants E1B F264A and E1B F285A still localized in discrete clusters, albeit with reduced efficiency in the case of E1B F285A (Figure 5a ; Supplementary Figures S2a  and b) . However, the substitution of phenylalanine 307 abolished the mutant's ability to form cytoplasmic clusters ( Figure 5a ). Moreover, its interaction with E4orf6 was defective (Figure 5b ), whereas mutants F264A and F285A could be relocalized by E4orf6 (Figure 5b ).
Next to F285, E1B-55 kDa contains another aromatic residue, Y286, raising the possibility that these two residues might functionally substitute for each other, resulting in partial but not complete functional impairment of E1B F285A. In agreement with this assumption, the double mutant FY285AA completely lost the ability to form cytoplasmic clusters (Figure 5a ). E1B FY285AA still associated with E4orf6 to some extent (Figure 5b ), arguing that it did not simply lose all known functions of E1B-55 kDa.
To confirm the failure of the E1B-55 kDa point mutants FY285AA and F307A to self-associate, we co-expressed them with differentially tagged wild-type E1B-55 kDa, followed by immunostaining. Whereas E1B F264A and F285A strongly associated with wildtype E1B-55 kDa, much less of this colocalization was seen for the E1B mutants FY285AA and F307A (Figures 5c and d) . Importantly, the same mutations also largely abolished the ability of E1B-55 kDa to bind itself in co-immunoprecipitations (Figure 5e ). E1B-55 kDa mutants F307A and FY285AA inefficiently antagonize p53 Next we determined the ability of E1B-55 kDa substitution mutants to associate with and inhibit p53. The E1B mutant F264A was still capable to move p53 to the cytoplasm, as determined by immunofluorescence analysis (Figure 6a ). In contrast, E1B F285A did so only to a lesser extent, and the mutants F307A and FY285AA did not detectably relocalize p53. In accordance, E1B F264A still reduced the transcriptional activity of p53 in reporter assays, but the mutants F285A, FY285AA and F307A were all impaired in this ability (Figure 6b) . Moreover, the same three mutants were less efficient than wild-type E1B-55 kDa regarding p53 degradation when co-expressed with E4orf6, albeit to varying degrees (Table 1 ; data not shown). We conclude that all point mutants of E1B-55 kDa that fail to selfassociate are also defective in their ability to associate with p53 and to reduce transactivation by p53. This is at least compatible with the assumption that the selfassociation of E1B-55 kDa might represent a prerequisite for p53 binding.
Interaction of E1B-55 kDa and p53 requires p53 tetramerization The fact that p53 forms a tetramer raised the questions whether the oligomerization of p53 would also contribute to the interaction of E1B-55 kDa and p53. To answer this, we used a truncated, oligomerizationdeficient mutant of p53 carrying a stop codon at position 332. Moreover, specific point mutations within the tetramerization domain of p53 were analyzed. H1299 cells were co-transfected to synthesize wild-type E1B-55 kDa and p53 mutants, followed by immunofluorescence analysis. As expected, wild-type p53 was efficiently relocalized by E1B-55 kDa from the nucleus to the cytoplasmic clusters (Figure 7a ). In contrast, p53 with mutations at the residues 22/23 remained nuclear (Figure 7a ), in agreement with its defective interaction with E1B-55 kDa (Lin et al., 1994) . Interestingly, p53 Stop332 and the monomeric p53 mutant KEEK also remained mostly nuclear, and only a small portion could be detected within the cytoplasmic clusters of E1B-55 kDa (Figure 7a) , as confirmed by quantification of the cells that contained cytoplasmic p53 (Figure 5b ). In contrast, a p53 mutant that forms dimers but not tetramers, p53 LLL, was almost completely relocalized to the cytoplasmic cluster by E1B-55 kDa (Figures 7a  and b) . We also used a dominant inhibitor of p53 oligomerization termed p53DD, a polypeptide that largely consists of p53 oligomerization domain. It competitively induces the formation of inactive heterooligomers with p53, eliminating p53 homotetramers (Shaulian et al., 1992) . When we co-expressed wild-type p53 with wild-type E1B-55 kDa and p53DD, p53 stayed mainly nuclear. However, when an inactive control construct p53DD deltaS was used, p53 relocalization was not disturbed (Figures 7a and b) .
Interestingly, the adenovirus type 12 E1B-55 kDa protein also relocalized wild-type p53 but not p53 Stop332 (Supplementary Figure S3) . Earlier studies had reported that p53 relocalization by Ad12 E1B-55 kDa does not depend on the oligomerization status of p53 (Zhao and Liao, 2003) . However, in those studies, a GFP-E1B Ad12 construct was used. GFP is known to dimerize on its own, perhaps representing the reason for the discrepancy.
Our results show that monomeric p53 retains only weak ability to associate with E1B-55 kDa. To further confirm this result, we performed co-immunoprecipitations of p53 and E1B-55 kDa. H1299 cells were cotransfected to synthesize wild-type E1B-55 kDa, as well as mutants and fragments of p53. Cell lysates were subjected to precipitations with an antibody against p53, Self-association of E1B-55 kDa M Morawska-Onyszczuk et al followed by immunoblot and staining of p53 and E1B-55 kDa. Analysis of the soluble and insoluble input fractions showed that mutant E1B-55 kDa was more soluble than the wild-type protein, apparently reflecting a reduced solubility of the cytoplasmic cluster formed by the latter (Figure 2a) . On co-expression with wild-type E1B-55 kDa, p53 was found less soluble, perhaps through its association with the cytoplasmic clusters. Self-association of E1B-55 kDa M Morawska-Onyszczuk et al
Wild-type E1B-55 kDa was coprecipitated with wildtype p53 but not with p53 Stop332 or control (Figure 7c) . Moreover, wild-type p53 and dimeric p53 LLL were rendered less soluble on addition of E1B-55 kDa. Monomeric p53 mutants (KEEK and Stop310), and control p53 22/23, stay in majority in soluble fraction, even if E1B-55 kDa is present (Figure 7d ). Thus, p53 solubility seems to decrease through association with E1B-55 kDa. We suggest that both p53 and E1B-55 kDa need to oligomerize for efficient mutual interaction, and this is due to increased avidity; that is, complex stabilization though multiple interactions, as known for the interaction between antigens and bi-or polyvalent antibodies. 
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Curiously, however, p53 does not require its oligomerization domain for degradation when both E1B-55 kDa and E4orf6 are present in the same cell (Figure 7e ), as previously described (Querido et al., 2001b) . This may be due to the ability of E1B-55 kDa (Sarnow et al., 1982a) as well as E4orf6 (Dobner et al., 1996) to interact directly with different regions on p53, possibly giving rise to a trimeric complex that is again held together through multiple interactions but without the need for p53 oligomerization.
E1B-55 kDa oligomerization allows for transcomplementation regarding the relocalization of p53
The point mutant R240A of E1B-55 kDa cannot bind p53 but can still interact with E4org6 and form cytoplasmic clusters (Shen et al., 2001) . The E1B-55 kDa mutant Stop396 also fails to antagonize p53 (Figure 4b ), perhaps as a result of its failure to form cytoplasmic clusters. We therefore hypothesized that E1B R240A, despite its inability to bind p53 on its own, might restore the association of E1B Stop396 with p53. Immunofluorescence analysis showed that the E1B R240A mutant can indeed form cytoplasmic clusters and relocalize E1B Stop396 to a similar extent as wildtype E1B-55 kDa (Figures 8a and b) . Although neither E1B Stop396 nor E1B R240A alone was capable of relocalizing p53 to the cytoplasm, their co-expression allowed the detection of p53 in cytoplasmic clusters (Figures 8c and d) . Oligomerization thus allows for trans-complementation and partially restores the ability of two defective mutants to associate with p53.
Discussion
The large E1B proteins of adenoviruses are prototype p53 antagonists; in fact, p53 and its importance in cancer were first discovered through its interaction with DNA tumor virus proteins (Berk, 2005; Levine, 2009 ). The results reported here indicate that the interference of E1B-55 kDa with p53 function is not merely determined by a simple bimolecular interaction. Instead, both partners need to self-associate to interact efficiently with each other. This principle may pertain to a large variety of binding partners that associate with E1B-55 kDa and/or with p53.
Avidity enables the interaction between E1B-55 kDa and p53
Multiple interactions within a higher-order complex of molecules can strongly enhance the stability of the complex as a whole, in a synergistic fashion. This phenomenon has first been described for antibodies: because immunoglobulin M antibodies contain 10 undistinguishable antigen binding sites (paratopes), the interaction with their epitopes is far stronger than the interaction observed between single Fab fragments and antigens, as long as the antigen is presented in aggregates with multiple epitopes of the same kind. This phenomenon has since then been designated by the term 'avidity' to distinguish the combined stability of such multiple interactions from the affinity of a single bond (Dissanayake et al., 1977) . Our results strongly suggest that the interaction between E1B-55 kDa and p53 requires a similar avidity phenomenon. Here again, the self-association of both partners is required for efficient interaction with each other.
p53 requires the ability to dimerize but does not need to form tetramers for its association with E1B-55 kDa. A simple avidity model would predict that tetramerization of p53 would further increase its association with E1B-55 kDa when compared with p53 dimers. The most straightforward explanation for the seeming discrepancy consists in the assumption that E1B-55 kDa predominantly forms dimers, leaving only two binding sites for a p53 oligomer. In agreement, dimers were observed when analyzing baculovirus-expressed E1B-55 kDa by gel filtration (Martin and Berk, 1998) . However, the large E1B protein from adenovirus type 12 was observed at molecular weights compatible with tetramers or even higher oligomers in a previous study (Grand et al., 1995) If transferable to the Ad2/Ad5 situation, this suggests that E1B-55 kDa complexes could provide at least four p53 binding sites at a time. Both studies were using in vitro assays, whereas our experiments support the view that E1B-55 kDa also self-associates in mammalian cells. However, it should be taken into account that a fourfold interaction between p53 and E1B-55 kDa would require considerable flexibility of both tetramers. In the case of immunoglobulin M, this flexibility is brought about by the adoption of a 'polyp'-like shape that allows the simultaneous binding of several paratopes to aggregated epitopes (Davis and Shulman, 1989 ). p53 and/or E1B-55 kDa cannot automatically 
Abbreviations: NA, not assigned; wt, wild type.
Self-association of E1B-55 kDa M Morawska-Onyszczuk et al be expected to provide the same degree of structural flexibility, possibly allowing only two p53 molecules within one tetramer to interact with an E1B-55 kDa oligomer.
Self-association of E1B-55 kDa co-segregates with the formation of cytoplasmic clusters For all the mutations within the central region of E1B-55 kDa analyzed here, their ability to self-associate coincided with the accumulation in cytoplasmic clusters. Mutants with a deletion in the C-terminal region of E1B-55 kDa also failed to form such clusters but did associate with wild-type E1B-55kDa in these structures. This argues that self-association is a prerequisite for the accumulation of E1B-55 kDa in this interesting intracellular location. Some reports have provided evidence that E1B-55 kDa accumulates in a structure termed 'aggresomes', characterized by high concentrations of vimentin (Liu et al., 2005) . However, others could not identify vimentin enrichment at the sites of E1B-55 kDa (Zhao and Liao, 2003) . In any case, it seems possible that E1B-55 kDa not only associates with preformed intracellular structures but actively shapes them or even leads to their formation in the first place. If E1B-55 kDa assumes such a role as a structure-defining element, its ability to self-associate could represent a key mechanism for doing so. We propose that high-order multimers could be formed by the aggregation of smaller-order complexes of E1B-55 kDa. In agreement with such a scenario, high-molecular-weight aggregates that contain E1B-55 kDa (and possibly additional components) have been observed in a previous study (Grand et al., 1995) . Moreover, we have consistently observed high-molecular-weight aggregates of E1B-55 kDa that are resistant to standard SDS-polyacrylamide electrophoresis conditions (data not shown). Although the biochemical nature of these aggregates is unclear at this point, they might reflect cluster formation in vivo. This is also supported by the notion that E1B-55 kDa relocates p53 to a less soluble fraction of cell lysates. We suppose that the accumulation of E1B-55 kDa and p53 in cytoplasmic clusters is associated with multiple protein aggregations and hence decreased solubility. Our mutational analysis defines a region within E1B-55 kDa that is required for self-association and proper E1B-55 kDa functioning (Table 1) . This raises the question whether this region is also sufficient to form oligomers when synthesized as a protein fragment. Our unpublished observations show that this is indeed the case. However, the response of such fragments to point mutations differs from that of full-length E1B-55 kDa (data not shown). It is therefore difficult to assess whether the self-association of E1B-55 kDa fragments maintains the same characteristics as whole E1B-55 kDa. We favor the view that the complex conformation of E1B-55 kDa does not allow its division into separate functional domains.
Interactions of E1B-55 kDa with partners other than p53 may also depend on self-association Besides p53, E1B-55 kDa is known to associate with a variety of viral and cellular proteins. The association of E1B-55 kDa with E4orf6 mostly co-segregates with E1B-55 kDa self-association in the mutational analysis presented here. An exception was observed in the case of E1B FY285AA, which was still partially relocalized to the nucleus when co-expressed with E4orf6 (Figure 5b) . But even there, a large fraction of E1B remained cytoplasmic. This could either indicate that E1B-55 kDa needs to form oligomers to associate efficiently with E4orf6. Alternatively, however, the region of E1B-55 kDa that binds E4orf6 might overlap with the region forming oligomers. Without being able to decide between these two possibilities, we favor the idea that E1B-55 kDa oligomers associate with E4orf6 more efficiently than monomers, but that E1B-55 kDa self-association is not an absolute requirement for E4orf6 binding. At present though, it is not known whether E4orf6 alone is capable of forming oligomers. Moreover, the interaction between E1B-55 kDa and E4orf6 is further complicated by the need for RUNX1 (Marshall et al., 2008) . The E4orf6 protein, rather than E1B-55 kDa, is the principal binding partner for cullin 5 and the ubiquitin ligase complex (Querido et al., 2001a; Harada et al., 2002) , making it an even more intriguing question whether and how E4orf6 forms higher-order complexes with itself or in association with E1B-55 kDa.
Another viral E1B-55 kDa association partner is E4orf3 (Konig et al., 1999; Leppard and Everett, 1999) . This protein, although highly insoluble and therefore difficult to study, forms large aggregates in the nucleus and cytoplasm (Araujo et al., 2005) , suggesting that it might self-associate. E4orf3 could hence provide another example of increased association with E1B-55 kDa through avidity. Figure 7 Impact of p53 oligomerization on its interaction with E1B-55 kDa. (a) Interaction of wild-type E1B-55 kDa with oligomerization-deficient p53. H1299 cells were co-transfected with plasmid encoding HA-tagged wild-type E1B-55 kDa (400 ng) and wild-type p53 (50 ng), p53 Stop332 (50 ng), p53 L22G T23S (50 ng) and the oligomerization competitor p53DD or its inactive mutant p53DDdeltaS (200 ng) as indicated. After 24 h, the cells were fixed and stained with rabbit HA Y-11 antibody specific for E1B-55 kDa, and the mouse monoclonal anti-p53 antibody (DO1). The rabbit FL393 antibody was used to visualize p53 L22G T23S mutant, as it is not recognized by DO1. The locations of the nuclei were visualized by 4 0 -6-diamidino-2-phenylindole (DAPI). Bar ¼ 20 mm. (b) Statistical evaluation of p53 relocalization to the cytoplasm. For each experiment, three samples of 50 cells each were counted by a person who was unaware of the identity of the samples. Cells with the majority of the p53's signal in the cytoplasm were counted as positive. The mean and standard deviation of the each sample are indicated for in each case. *Po0.00005. (c) Detection of p53/E1B-55 kDa interaction by co-immunoprecipitation. H1299 cells were transfected with 100 ng of a p53 expression constructs and 2 mg of E1B-55 kDa expression plasmids as indicated. After 24 h, the cell lysates were subjected to immunoprecipitation with the FL393 antibody against p53. 2% of the soluble input, 15% of insoluble input and 20% of the immunoprecipitate were analyzed by immunoblotting with anti-HA and DO1 (anti-p53) antibodies (the later antibody directly coupled to horseradish peroxidase) b-Actin staining served as loading control. P53 and b-actin staining were performed consecutively on the same blot. Therefore p53 Stop332 can be observed in the b-actin panel indicated by an asterisk. Note the different solubility of wild-type E1B-55 kDa and wild-type p53 when they were co-expressed, in comparison with the E1B-55 kDa mutants. (d) Detection of p53/E1B-55 kDa interaction by changed p53 solubility. H1299 cells were transfected with 50 ng of a p53 expression constructs and 500 ng of E1B-55 kDa expression plasmid as indicated. After 24 h the cell lysates were prepared by incubation with lysis buffer (as described for immunoprecipitation (IP)) for 1 h on ice. Subsequently, soluble lysates were analyzed by immunoblotting with anti-HA and Fl393 (anti-p53) antibodies. Enhanced green fluorescent protein (EGFP) staining served as transfection control. (e) Ability of p53 oligomerization mutants to be degraded on co-expression with E1B-55 kDa and E4orf6. H1299 cells were transfected with plasmids to express p53 (50 ng), E1B-55 kDa (150 ng) and E4orf6 (450 ng), or 'empty' vectors as indicated. After 24 the cells were harvested, followed by immunoblot analysis with the indicated antibodies. EGFP and b-actin served as transfection and loading controls, respectively.
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Concerning cellular proteins, and on top of p53, E1B-55 kDa associates with mediators of the DNA damage response and DNA repair. Namely, the MRN complex (Stracker et al., 2002) and the associated DNA ligase IV are subject to degradation by E1B-55 kDa and E4orf6. Interestingly, the MRN complex can form higher oligomers to achieve the association of DNA ends (de Jager et al., 2001) . It is therefore conceivable that the association with the MRN complex is also based on E1B-55 kDa self-association and the resulting increase in avidity. Other association partners of E1B-55 kDa, such as DNA ligase IV (Baker et al., 2007) , Integrin a3 (Dallaire et al., 2009) or the single-stranded DNA-binding protein 2 (Fleisig et al., 2007) , are not (yet) known to oligomerize but may possibly form similar complexes. p53 oligomerization may increase its avidity to associate with many binding partners p53 is known to associate with a large variety of cellular proteins, and our study on E1B-55 kDa raises the question whether the ability of p53 to form tetramers contributes to at least some of these associations.
In the case of viral proteins, it is noteworthy that the SV40 large T antigen, a known p53 binding oncoprotein, forms hexamers. It would be tempting to speculate that, again, this would provide a basis for efficient interaction with a p53 tetramer. However, the crystal structure of the complex rather suggests that T antigen disrupts the ability of p53 to form oligomers through massive conformational changes (Lilyestrom et al., 2006) . Apparently, the affinity of T antigen to p53 is Self-association of E1B-55 kDa M Morawska-Onyszczuk et al sufficient to bind p53 monomers without the need for higher-order complex formation. In contrast, the principal cellular p53 antagonist, Mdm2, has been found to form oligomers either with itself or with its paralogue MdmX/Mdm4 (Singh et al., 2007) . Moreover, the oligomerization of p53 is required for its degradation through Mdm2 (Kubbutat et al., 1998; Maki, 1999) . Together, these findings strongly suggest that the interaction of Mdm2 and p53, or at least the subsequent ubiquitin ligation, are fortified by an avidity effect analogous to the E1B-55 kDa/p53 interaction.
Many additional interaction partners of p53 have not been assessed as to their capability to self-associate. This includes histone acetyltransferases, kinases and numerous other direct or indirect modifiers of its activity (Bode and Dong, 2004) . A majority of these modifiers is found in large protein complexes. This raises the intriguing possibility that the stabilization of associations between p53 and its partners through avidity effects is a general phenomenon that reaches far beyond the interaction with adenovirus E1B-55 kDa.
Materials and methods
Cells and transfections H1299 cells were a kind gift of Arnold J Levine and maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum. H1299 cells were transfected with Lipofectamine 2000 (Invitrogen, Karlsruhe, Germany). Cells were seeded 24 h before transfection, on plastic slides (Nunc, Langenselbold, Germany) or 24-well dishes at 50 000 cells per well, or on 6-well dishes at 200 000 cells per well. Transfections were performed by combining 2 ml Lipofectamine 2000 with 650 ng plasmid for plastic slides (Nunc) or 24-well dishes, or 10 ml Lipofectamine 2000 with 2000 ng plasmid for 6-well dishes.
Plasmids
The expression plasmids for p53, p53 22/23 (Lin et al., 1994) , HA-tagged Ad12 E1B-55 kDa (Wienzek et al., 2000) , HAtagged Ad5 E1B-55kDa (termed pCGNE1B) and E4orf6 (Dobbelstein et al., 1997) , and a p53-responsive firefly luciferase reporter plasmid termed pBP100luc (Roth et al., 1998) have been described. The plasmids p53DD and p53DDS were kind gifts of Moshe Oren. The plasmids p53 LLL (L373, L380, L387) and p53 KEEK (K341, E344, E348, K355) were kind gift of Karen Vousden. All of the mutant plasmids were created by site-directed mutagenesis (QuikChange; Stratagene, Offenbach, Germany), using primers described in the Supplementary Material.
Co-immunoprecipitation H1299 cells seeded in six-well dishes were transfected with plasmids as indicated in the figure legends. After 24 h, the cells were harvested in 700 ml lysis buffer (50 mM Tris (pH 7.5), 150 mM NaCl, 0.5% NP-40) and mechanically disrupted with a syringe. The soluble fraction was precleared for 1 h with 30 ml of a 50% slurry of Protein sepharose CL-4B, followed by incubation with antibodies (0.5 mg) against the HA tag (HA.11; Covance, Mu¨nster, Germany) or p53 (FL393; Santa Cruz, Heidelberg, Germany) for 2 h. Protein-antibody complexes were pulled down for 30 min with 10 ml of a 50% slurry of Protein A sepharose (for HA.11) or Protein G sepharose (for FL-393), and washed five times with lysis buffer. Co-precipitated proteins were eluted from the sepharose by boiling with 50 ml of sample buffer (0.35 M Tris (pH 6.8), 30% glycerol, 10% SDS, 9.3% dithiothreitol, 0.02% bromophenol blue), resolved by SDS-polyacrylamide electrophoresis and detected by immunoblot analysis.
Immunoblot and immunofluorescence analyses as well as reporter assays were carried out as detailed in the Supplementary material.
